News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Amicus Therapeutics, Inc. (FOLD) Announces Updated Results From Phase 2 Extension Study of Migalastat HCl for Fabry Disease


11/5/2012 9:30:23 AM

CRANBURY, N.J., Nov. 5, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced updated data from an open-label, Phase 2 extension study (Study 205/FAB-CL-205) to investigate the long-term safety, tolerability and pharmacodynamics of migalastat HCl in 23 patients with Fabry disease who completed an initial Phase 2 study. Amicus in collaboration with GlaxoSmithKline (GSK) is developing the investigational pharmacological chaperone Migalastat HCl for the treatment of Fabry disease. Results1 from Study 205 were presented at the American Society of Nephrology (ASN) Kidney Week 2012.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES